Navigation Links
Technology deal for next generation production of 'green whistle'

Australian healthcare company Medical Developments International (MDI) and CSIRO have signed a technology deal to develop a new production process for the drug methoxyflurane the pain-relieving ingredient used in Penthrox (commonly known as the green whistle).

If successful, the project will help MDI significantly reduce the cost of producing Penthrox and facilitate large-scale production to support the company's plan to sell Penthrox in the UK and Europe.

CSIRO is investing $750 000 under its Australian Growth Partnerships (AGP) program into the project which will strengthen MDI's position as the only global manufacturer of methoxyflurane.

MDI is seeking regulatory approval to sell the drug in the United Kingdom and Europe, which if granted, will see MDI increase production of the drug using CSIRO's manufacturing process.

Penthrox is used in Australia as an analgesic by emergency medical practitioners, the defence forces, ambulance and surf lifesaving services. Recently its applications have expanded into dentistry, general practitioners, cosmetics and other medical specialities such as endoscopy.

Penthrox has significant advantages over other analgesics such as nitrous oxide and morphine in that it is fast acting, self-administered, non-addictive, non-narcotic and safe to use and provides strong pain relief.

John Sharman, CEO of MDI, said: "The green whistle is already an iconic Australian product which we believe will offer an effective alternative to established products used in hospitals and emergency services in the UK, Europe and other parts of the world. Through our partnership with CSIRO, we hope to scale-up the production of methoxyflurane by developing a smarter, more efficient manufacturing process and in so doing assist MDI deliver on its promising future."

Paul Savage, CSIRO biotechnology program leader said: "Our AGP program is an excellent example of how innovative SMEs can access CSIRO's world-class research and development capability. This partnership demonstrates how forward-thinking Australian companies can benefit from R&D to grow locally and to expand into global markets."

Penthrox is made in Melbourne and sold in 11 countries around the world with regulatory applications pending approval in another 15 countries.

Australian companies CSIRO has invested in via its AGP program include Biofiba, Clover Corporation and Avipep.

Contact: Simon Hunter
CSIRO Australia

Related biology news :

1. Advanced Membrane Technology V Conference
2. University of North Texas Health Science Center Advances Forensic Research by Investing in Semiconductor DNA Sequencing Technology
3. Next-generation sequencing technology opens doors to discoveries
4. Weizmann Institute solar technology to convert greenhouse gas into fuel
5. Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information
6. Nanotechnology breakthrough could dramatically improve medical tests
7. NIH-funded study examines use of mobile technology to improve diet and physical activity behavior
8. New study shows how nanotechnology can help detect disease earlier
9. Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information
10. Purdue professor to speak before Congress about nanotechnology in brain treatment research
11. AAPS National Biotechnology Conference to highlight innovative vaccines
Post Your Comments:
(Date:11/18/2015)... new scientific discoveries deepen our understanding of how cancer ... challenges in better using that knowledge to guide treatment ... children continue to survive pediatric cancer, that counseling may ... John M. Maris, M.D ., a pediatric oncologist ... --> John M. Maris, M.D ., ...
(Date:11/17/2015)... , November 17, 2015 Paris ...   --> Paris from 17 th ... DERMALOG, the biometrics innovation leader, has invented the first combined ... on the same scanning surface. Until now two different scanners ... one scanner can capture both on the same surface. ...
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... ... , ... The Academy of Model Aeronautics (AMA), led by its Executive Council, ... Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing has ... type of racing and several new model aviation pilots have joined the community because ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology: